WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 530406
CAS#: 76472-29-2 (mesylate)
Description: Ono-3307 is a protease inhibitor potentially for the treatment of thrombosis. ONO-3307 competitively inhibited trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein and chymotrypsin; and their Ki values were 0.048 microM, 0.18 microM, 0.29 microM, 0.31 microM, 3.6 microM and 47 microM, respectively. In addition, ONO-3307 inhibited both elastase release from N-formyl-Met-Leu-Phe (fMLP)-stimulated leukocytes and tissue thromboplastin release from endotoxin-stimulated leukocytes. ONO-3307 exhibits a wide range of inhibitory effects on various proteases, and ONO-3307 may be useful for the treatment of protease-mediated diseases such as thrombosis and DIC.
MedKoo Cat#: 530406
Name: Ono-3307 mesylate
CAS#: 76472-29-2 (mesylate)
Chemical Formula: C15H18N4O7S2
Molecular Weight: 430.45
Elemental Analysis: C, 41.86; H, 4.22; N, 13.02; O, 26.02; S, 14.90
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Ono-3307 mesylate; Ono-3307; Ono 3307; Ono3307.
IUPAC/Chemical Name: 4-sulfamoylphenyl 4-guanidinobenzoate methanesulfonate
InChi Key: OSILTPUZIFPGFS-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H14N4O4S.CH4O3S/c15-14(16)18-10-3-1-9(2-4-10)13(19)22-11-5-7-12(8-6-11)23(17,20)21;1-5(2,3)4/h1-8H,(H4,15,16,18)(H2,17,20,21);1H3,(H,2,3,4)
SMILES Code: O=C(OC1=CC=C(S(=O)(N)=O)C=C1)C2=CC=C(NC(N)=N)C=C2.CS(=O)(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 430.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Hirano T, Manabe T, Steer M, Printz H, Calne R, Tobe T. Protective effects of therapy with a protease and xanthine oxidase inhibitor in short form pancreatic biliary obstruction and ischemia in rats. Surg Gynecol Obstet. 1993 Apr;176(4):371-81. PubMed PMID: 8460415.
2: Sobajima H, Hayakawa T, Kondo T, Shibata T, Kitagawa M, Sakai Y, Ishiguro H, Tanikawa M, Nakae Y. Effect of a new synthetic trypsin inhibitor on taurocholate-induced acute pancreatitis in rats. Pancreas. 1993 Mar;8(2):240-7. PubMed PMID: 8460097.
3: Ono S, Tamakuma S, Mochizuki H, Kinoshita M, Ohkusa Y, Aosasa S, Oda Y, Ohe H. Clinical and experimental studies on the role of platelet-activating factor (PAF) in the pathogenesis of septic DIC. Surg Today. 1993;23(3):228-33. PubMed PMID: 8467174.
4: Hirano T, Manabe T, Tobe T. Impaired hepatic energy metabolism in rat acute pancreatitis: protective effects of prostaglandin E2 and synthetic protease inhibitor ONO 3307. J Surg Res. 1992 Sep;53(3):238-44. PubMed PMID: 1528049.
5: Hirano T, Manabe T, Tobe T. Cytoprotective effects of prostaglandins and a new potent protease inhibitor in acute pancreatitis. Am J Med Sci. 1992 Sep;304(3):154-63. PubMed PMID: 1282294.
6: Hirano T, Manabe T, Ohshio G, Nio Y. Protective effects of combined therapy with a protease inhibitor, ONO 3307, and a xanthine oxidase inhibitor, allopurinol on temporary ischaemic model of pancreatitis in rats. Nihon Geka Hokan. 1992 May 1;61(3):224-33. PubMed PMID: 1444702.
7: Hirano T, Manabe T, Calne R, Tobe T. Effects of acute pancreatitis on hepatic secretion of lysosomal enzymes into bile and hepatic lysosomal fragility: protective effects of a new synthetic protease inhibitor, ONO 3307. Scand J Gastroenterol. 1992;27(3):227-32. PubMed PMID: 1502486.
8: Hirano T, Manabe T, Tobe T. Protection by a new synthetic protease inhibitor, ONO3307, of the rat exocrine pancreas during acute edematous pancreatitis induced by a supramaximal dose of caerulein in comparison with FOY007. Pharmacology. 1992;45(2):107-16. PubMed PMID: 1381836.
9: Hirano T, Yotsumoto TM, Ando K, Tobe T. [Changes of acinar cells in the pancreato-biliary duct ligation with exocrine pancreatic stimulation model in rats; protective effects of a new potent protease inhibitor, ONO3307]. Nihon Geka Hokan. 1991 Sep 1;60(5):342-53. Japanese. PubMed PMID: 1726453.
10: Yoshikawa T, Takeda S, Naito Y, Kondo M. Protective effects of ONO-3307, a new synthetic protease inhibitor against experimental disseminated intravascular coagulation in rats. Thromb Res. 1990 Oct 1;60(1):1-7. PubMed PMID: 2278034.
11: Matsuoka S, Futagami M, Ohno H, Imaki K, Okegawa T, Kawasaki A. Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63. PubMed PMID: 2515329.
76472-28-1 (Ono-3307 Free)
76472-29-2 (Ono-3307 mesylate)